Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | METAP1 | P53582 | 2/20 | 0.52 |
| ▸ | S100A4 | P26447 | 1/20 | 0.50 |
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | ROS1 | P08922 | 1/20 | 0.43 |
| ▸ | MARK3 | P27448 | 1/20 | 0.43 |
| ▸ | LTK | P29376 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10057541 | 0.87 | TDP1 (0.63) | TDP1L3MBTL1CES1METAP1S100A4 | |
| SCHEMBL2370367 | 0.87 | METAP1 (0.50) | TDP1L3MBTL1CES1BCHEMETAP1 | |
| SCHEMBL30648614 | 0.82 | METAP1 (0.50) | TDP1L3MBTL1CES1BCHEMETAP1 | |
| SCHEMBL29120739 | 0.82 | METAP1 (0.50) | TDP1L3MBTL1CES1BCHEMETAP1 | |
| SCHEMBL27761880 | 0.82 | METAP1 (0.65) | TDP1L3MBTL1CES1METAP1S100A4 | |
| SCHEMBL31073 | 0.80 | METAP1 (0.79) | TDP1L3MBTL1CES1METAP1S100A4 | |
| SCHEMBL25920001 | 0.80 | TDP1 (0.51) | TDP1L3MBTL1CES1METAP1S100A4 | |
| SCHEMBL30960433 | 0.79 | TDP1 (0.54) | TDP1L3MBTL1CES1BCHEMETAP1 | |
| SCHEMBL394145 | 0.79 | TDP1 (0.80) | TDP1L3MBTL1CES1BCHEMETAP1 | |
| SCHEMBL4608851 | 0.79 | TDP1 (0.54) | TDP1L3MBTL1CES1BCHEMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6127189-A | CONTACTING WITH A 1,2-INDANEDIONE DERIVATIVE, MEASURING ABSORBANCE OR FLUORESCENCE OF PRODUCT FORMED, AND COMPARING TO STANDARDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-10-03 | — | — | US | claimed |
| WO-1998020344-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF AN AMINE COMPOUND | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-05-14 | — | — | WO | claimed |
| US-11643414-B2 | Materials for organic electroluminescent devices | MERCK PATENT GMBH (DE) | 2023-05-09 | — | — | US | disclosed |
| US-9827226-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2017-11-28 | — | — | US | disclosed |
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2017-02-02 | — | — | US | disclosed |
| US-9393232-B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | BEIGENE, LTD. (KY) | 2016-07-19 | — | — | US | disclosed |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BEONE MEDICINES I GMBH (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-8921369-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877707-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8703798-B2 | Antifungal and antiparasitic indoloquinoline derivatives | FLORIDA A&M UNIVERSITY (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120157493-A1 | Antifungal and Antiparasitic Indoloquinoline Derivatives | FLORIDA A&M UNIVERSITY (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7374580-B2 | Dyeing compositions comprising A 1,2-indandione derivative | L'OREAL S.A. (FR) | 2008-05-20 | — | — | US | disclosed |
| US-7374580-B2 | Dyeing compositions comprising A 1,2-indandione derivative | L'OREAL S.A. (FR) | 2008-05-20 | — | — | US | disclosed |
| US-6127189-A | CONTACTING WITH A 1,2-INDANEDIONE DERIVATIVE, MEASURING ABSORBANCE OR FLUORESCENCE OF PRODUCT FORMED, AND COMPARING TO STANDARDS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-10-03 | — | — | US | disclosed |
| WO-1998020344-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF AN AMINE COMPOUND | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027912-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BRD4, BRPF3, BRD3 | TDP1 1354/4885L3MBTL1 1856/4885CES1 3008/4885 |
| US-20130096101-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | TDP1 4284/4885L3MBTL1 3448/4885CES1 352/4885 |
| US-20120122864-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | TDP1 4237/4885L3MBTL1 3523/4885CES1 281/4885 |
| US-20150057218-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | TDP1 4237/4885L3MBTL1 3523/4885CES1 281/4885 |
| US-20120157493-A1 | Antifungal and Antiparasitic Indoloquinoline Derivatives | IDO1, IDO2, IMMT | TDP1 2495/4885L3MBTL1 238/4885CES1 1019/4885 |
| US-20130203656-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | TDP1 4237/4885L3MBTL1 3523/4885CES1 281/4885 |
| US-11643414-B2 | Materials for organic electroluminescent devices | SLCO4C1, SLCO2A1, PIEZO1 | TDP1 1988/4885L3MBTL1 2364/4885CES1 4027/4885 |
| US-20160030395-A1 | SUBSTITUTED 5-(3,5-DIMETHYLISOXAZOL-4-YL)INDOLINE-2-ONES | BRD4, BRPF3, BRD3 | TDP1 1354/4885L3MBTL1 1856/4885CES1 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.